We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Hematologic Complications with Age in Shwachman-Diamond Syndrome

By LabMedica International staff writers
Posted on 24 Jan 2022
Print article
Image: Bone marrow biopsy from a patient with severe Shwachman-Diamond Syndrome, hypocellular marrow; scattered mild dysplastic changes in all cell lines; may have prominent hematogones (Photo courtesy of Dragos C. Luca, MD)
Image: Bone marrow biopsy from a patient with severe Shwachman-Diamond Syndrome, hypocellular marrow; scattered mild dysplastic changes in all cell lines; may have prominent hematogones (Photo courtesy of Dragos C. Luca, MD)
Shwachman-Diamond syndrome (SDS) is a rare, inherited bone marrow failure, characterized by a low number of white blood cells, poor growth due to difficulty absorbing food, exocrine pancreatic dysfunction, and, in some cases, skeletal abnormalities.

Children with SDS have a small but significant chance of developing blood disorders such as myelodysplastic syndrome (MDS) or leukemia. Nearly 5% of children with the condition will develop leukemia, with the risk rising to 25 % by adulthood. In addition, recurring infections, including pneumonia, ear, and skin infections, are common.

A large team of medical scientists led by those at Harvard Medical School (Boston, MA, USA) conducted a cohort study of 153 subjects from 143 families with confirmed biallelic SBDS mutations enrolled on the North American Shwachman Diamond Registry or Bone Marrow Failure Registry. The team collected longitudinal complete blood counts (CBCs). CBCs were included until the time of myelodysplasia (MDS) or leukemia diagnosis or until the time of hematopoietic stem cell transplant (HSCT), when applicable.

Hemoglobin values were excluded during periods of red cell transfusions, platelet values were excluded during platelet transfusions, and absolute neutrophil counts (ANCs) were excluded while on granulocyte colony-stimulating factor (G-CSF). Local bone marrow aspirate and biopsy reports were examined for reported cellularity (from biopsies), fluorescence in situ hybridization, karyotype, and flow cytometry data. Surveillance bone marrows were defined as bone marrow examinations performed in the absence of clinical symptoms.

The investigators reported that 153 individuals (143 families) with biallelic SBDS mutations, including several short case descriptions illustrating the diversity of phenotypes in SDS. Ninety-two were male (60.1%). Median age at last follow-up was 10.4 years (range, 0.3-52.8). The cohort included 39 adults (25.5%) who were >18 years of age at the follow-up. The SBDS c.258 + 2T>C variant was present in all but one patient.

The team evaluated the association between blood counts and age, 2,146 blood counts were analyzed for 119 subjects. Absolute neutrophil counts were positively associated with age. Hemoglobin was also positively associated with age up to 18 years, but the association was negative thereafter. Platelet counts and marrow cellularity were negatively associated with age. Marrow cellularity did not correlate with blood counts. Severe marrow failure necessitating transplant developed in eight subjects at a median age of 1.7 years (range, 0.4-39.5), with 7/8 requiring transplant prior to age 8 years. Twenty-six subjects (17%) developed a myeloid malignancy (16 myelodysplasia and 10 acute myeloid leukemia) at a median age of 12.3 years (range, 0.5-45.0) and 28.4 years (range, 14.4-47.3), respectively.

The authors concluded that their study found that, although marrow cellularity decreased with age, as expected for a genetic bone marrow failure (BMF) condition, blood counts unexpectedly improved with age. Severe BMF was observed in early childhood, whereas myeloid malignancy was observed in later childhood/early adulthood. The study was published on January 11, 2022 in the journal Blood Advances.

Related Links:
Harvard Medical School

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.